Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)

Historic Asset Writedowns and Impairment for BridgeBio Pharma (BBIO) over the last 2 years, with Q3 2022 value amounting to $67000.0.

  • BridgeBio Pharma's Asset Writedowns and Impairment changed N/A to $67000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was $67000.0, marking a year-over-year decrease of 9928.37%. This contributed to the annual value of $271000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that BridgeBio Pharma reported Asset Writedowns and Impairment of $67000.0 as of Q3 2022.
  • Over the past 5 years, BridgeBio Pharma's Asset Writedowns and Impairment peaked at $12.7 million during Q1 2022, and registered a low of -$3.3 million during Q4 2021.